Swiftmerge Acquisition Corp. Takes HDL Therapeutics Public in $400 Million Transaction

Swiftmerge Acquisition Corp. Takes HDL Therapeutics Public in $400 Million Transaction

by | Aug 15, 2023 2:11 pm | Biotechnology

On August 11, Swiftmerge Acquisition Corp., a West Vancouver-based special purpose acquisition company, announced that it was taking HDL Therapeutics Inc. public through a merger.   HDL Therapeutics is a biotech innovator, focused on developing first-in-class treatments for intractable cardiovascular and neurovascular diseases using the company’s proprietary technology platform. The holders of the outstanding HDL Therapeutics preferred stock and common stock will receive a combination of cash and equity in Swiftmerge totaling $400 million. The business combination values the combined company at approximately $480 million. Upon closing of the merger, Swiftmerge will change its... Read More »
Eli Lilly to Acquire Boston-Based Biotech Versanis

Eli Lilly to Acquire Boston-Based Biotech Versanis

by | Jul 14, 2023 11:40 am | Biotechnology

Eli Lilly and Company and Versanis announced on July 14 a definitive agreement for Lilly to acquire Versanis. Under the terms of the agreement, Versanis shareholders could receive up to $1.925 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain development and sales milestones. Versanis is a Boston-based, clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling. Eli Lilly and Company is headquartered in Indianapolis,... Read More »
Eli Lilly to Acquire Boston-Based Biotech Versanis

Baudax Bio Acquires TeraImmune

by | Jun 30, 2023 2:05 pm | Biotechnology

Baudax Bio, Inc. announced on June 30 that it acquired TeraImmune, Inc.  TeraImmune is a privately held biotechnology company working on cell therapies for autoimmune diseases. Key technical assets of TeraImmune include expansion of human regulatory T cells in vitro and receptors targeting pathological immune cells (T cell/ B cell/ antigen presenting cell). Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing products for acute care settings. The company has multiple non-opioid therapeutics in clinical development for the treatment of pain conditions and is currently promoting their lead product, ANJESO™, indicated for use in adults for the... Read More »
Swiftmerge Acquisition Corp. Takes HDL Therapeutics Public in $400 Million Transaction

​​Talaris Therapeutics Merges with Tourmaline Bio

by | Jun 23, 2023 3:14 pm | Biotechnology

Talaris Therapeutics, Inc. announced on June 22 that it entered an agreement to merge with Tourmaline Bio, Inc. According to data captured in the LevinPro HC database, this transaction represents the 76th Biotechnology transaction of 2023.  Talaris stockholders are expected to receive $3.43 per Talaris share for a total price of more than $144.62 million. Tourmaline stockholders are expected to own 78.7% of the combined company and Talaris stockholders are expected to own 21.3% of the combined company, each on a fully diluted basis. Talaris anticipates making a cash dividend of up to approximately $64.8 million to its stockholders prior to the closing of the Merger. Talaris Therapeutics is... Read More »
Eli Lilly to Acquire Boston-Based Biotech Versanis

Pyxis Oncology Acquires Apexigen

by | May 25, 2023 1:56 pm | Biotechnology

Pyxis Oncology announced on May 24 that it acquired Apexigen, Inc. for $16 million.  Founded in 2010, Apexigen, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology. Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates and immunotherapies. It is funded by the Longwood Fund, a Boston-based venture capital firm.  This acquisition was announced nearly a year after Apexigen went public by a merger with Brookline Capital Acquisition Corp.  According to data captured in the LevinPro HC database, this acquisition represents the 61st... Read More »
Swiftmerge Acquisition Corp. Takes HDL Therapeutics Public in $400 Million Transaction

Bavarian Nordic Closes Acquisition of Emergent BioSolutions’ Travel Health Business

by | May 22, 2023 3:16 pm | Biotechnology

Gaithersburg, Maryland-based Emergent BioSolutions Inc., a specialty biopharmaceutical company, announced that it closed on the sale of its portfolio of travel vaccines to Bavarian Nordic. The transaction was initially announced on February 15, 2023.  The portfolio includes Vivotif and Vaxchora, which prevent typhoid fever and cholera, respectively. Emergent BioSolutions is also selling a Phase III vaccine candidate for the prevention of Chikungunya virus. Emergent received $270 million and may receive up to an additional $110 million in potential future milestone payments. Wells Fargo Securities, LLC served as financial advisor, and Barnes & Thornburg LLP served as legal counsel... Read More »